Deslorelin Implant PK/PD Control for Predictable Chemical Castration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing deslorelin implants for chemical castration in non-human mammals exhibit unpredictable pharmacokinetic/pharmacodynamic (PK/PD) relationships, leading to undesirable 'flare-up' effects and varying efficacy durations, with a lack of clear thresholds for maintaining effective concentrations.
Innovation Solution
Administer deslorelin to achieve a maximum concentration (Cmax) of 7000 pg/mL within 1-2 hours post-administration, followed by sustained plasma concentrations between 10-400 pg/mL for at least 6 months using a biodegradable polymer implant, ensuring a consistent therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deslorelin is administered continuously to suppress gonadotropin release, then contraceptive efficacy is improved, but unpredictable flare-up effects occur due to lack of clear PK/PD thresholds
Solution Approach 1:
The patent establishes specific concentration thresholds for deslorelin (Cmax ≥ 7000 pg/mL at 1-2 hours, then 10-400 pg/mL maintenance) to control the flare-up effect. By changing the dosing parameters to achieve these specific concentration levels, the patent resolves the contradiction between maintaining contraceptive efficacy and preventing harmful flare-up effects.
Solution Approach 2:
The patent uses PK/PD relationship feedback to adjust dosing regimens. By monitoring deslorelin concentrations and their relationship to gonadotropin suppression, the patent optimizes dosing to maintain therapeutic levels while avoiding excessive concentrations that cause flare-up effects.
2Reliability
If deslorelin implant releases high initial concentration to ensure efficacy, then contraceptive effect is improved, but duration of action becomes unpredictable
Solution Approach 1:
The patent implements a two-phase dosing strategy: an initial high-concentration phase (Cmax ≥ 7000 pg/mL) to ensure rapid onset of contraceptive effect, followed by a maintenance phase (10-400 pg/mL) to sustain efficacy. This periodic action pattern resolves the contradiction between achieving reliable contraceptive effect and ensuring predictable duration.
Solution Approach 2:
The patent applies preliminary high-dose deslorelin administration to rapidly achieve therapeutic concentrations and suppress gonadotropins before transitioning to lower maintenance doses. This preliminary action ensures immediate contraceptive efficacy while the maintenance phase ensures predictable long-term duration.
3Object-generated harmful factors
If deslorelin concentration is maintained at high levels to prevent flare-up, then harmful effects are reduced, but therapeutic efficacy may be insufficient
Solution Approach 1:
The patent employs dynamic dosing that changes over time: high initial concentration to suppress flare-up, then transition to maintenance concentrations optimized for therapeutic efficacy. This dynamic approach resolves the contradiction by adapting the concentration level to different phases of treatment rather than maintaining a static high level throughout.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach stabilizes testosterone levels below 0.4 ng/mL and induces temporary infertility or suppresses sexual behaviors in non-human mammals for an extended period, overcoming the variability in existing implants by establishing a clear PK/PD relationship.
Implementation Method 1
designing a deslorelin implant that continuously diffuses a GnRH agonist (deslorelin)
Data Source
AI summary
Deslorelin, in a medicinal or a non-medicinal product, for its use in chemical castration of a non-human mammal within 1 month after administration, wherein upon administration, the Cmax of deslorelin, at around 1 to 2 hours after administration, exceeds 7000 pg/mL and a deslorelin concentration in the non-human mammal plasma is at least 10 pg/mL. Also, a sustained release drug delivery system for implementing this use. Further, a method for chemically castrating a non-human animal including the steps of (a) administering an effective amount of deslorelin so as to obtain a Cmax concentration between 4000 pg/mL and 40000 pg/ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof within first 24 h after injection; and thereafter, (b) administering a maintenance dose so that mean concentration is above 10 pg/ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof.